Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 282 0507

Website: www.ataibeckley.com

Address:

250 West 34th Street, New York, United States

Ferg500 Feb. 27 at 9:17 PM

$ATAI Just now seeing this figured I'd reshare https://x.com/c_angermayer/status/2027419503995342934?s=46

0 · Reply

Sailingsoon Feb. 27 at 9:14 PM

$ATAI interesting week, very nervous and at least for me, not explainable. I think high level expectations vs moderate informal updates. Sprint vs Marathon I think the solid statement today from ATAI will level it and the hope for the update on the 6th. The Analyst prognoses mentioned for 2026 not for Feb. 2026

0 · Reply

Risk1123 Feb. 27 at 9:13 PM

$ATAI more to come

0 · Reply

GSTX7 Feb. 27 at 8:48 PM

$ATAI Ok. Back in.

0 · Reply

ASTB14 Feb. 27 at 8:39 PM

$ATAI Very great initial data seriously, it proved a lot, and they hit their primary goal (safety), everything else is the cherry on top.

0 · Reply

Bruv99669 Feb. 27 at 7:30 PM

$ATAI

0 · Reply

MexicoCity Feb. 27 at 7:30 PM

$ATAI

0 · Reply

Flarelords Feb. 27 at 7:30 PM

$ATAI Hopefully we can get some more info on investor day next week - looking forward to seeing what comes of it

0 · Reply

Georggggie Feb. 27 at 7:30 PM

$ATAI Really solid tweet by Christian think it was needed.

0 · Reply

Don_Brooks Feb. 27 at 7:29 PM

$ATAI

0 · Reply

AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript

Feb 26, 2026, 9:49 AM EST - 1 day ago

AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data

Feb 26, 2026, 7:00 AM EST - 1 day ago

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Feb 20, 2026, 7:00 AM EST - 7 days ago

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Jan 16, 2026, 7:00 AM EST - 6 weeks ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 8, 2026, 7:00 AM EST - 7 weeks ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 2 months ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Nov 19, 2025, 7:32 PM EST - 3 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 11, 2025, 9:21 AM EST - 3 months ago

Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript

Oct 20, 2025, 5:29 PM EDT - 4 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 9:00 AM EDT - 4 months ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 16, 2025, 10:31 PM EDT - 4 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 4 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 13, 2025, 2:21 PM EDT - 4 months ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 1, 2025, 2:40 PM EDT - 5 months ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Sep 23, 2025, 2:50 PM EDT - 5 months ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 7:00 AM EDT - 5 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 9, 2025, 6:59 AM EDT - 6 months ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Aug 28, 2025, 4:05 PM EDT - 6 months ago

atai Life Sciences to Participate in September Investor Conferences

Jul 28, 2025, 5:01 PM EDT - 7 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 10:58 AM EDT - 7 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 7 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 7 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 7 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 2:29 PM EDT - 8 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 1, 2025, 9:28 AM EDT - 8 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 8 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 8 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 9 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 9 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 10 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 10 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 10 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 1 year ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 1 year ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 11:57 AM EST - 1 year ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS HELP DFTX

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Ferg500 Feb. 27 at 9:17 PM

$ATAI Just now seeing this figured I'd reshare https://x.com/c_angermayer/status/2027419503995342934?s=46

0 · Reply

Sailingsoon Feb. 27 at 9:14 PM

0 · Reply

Risk1123 Feb. 27 at 9:13 PM

$ATAI more to come

0 · Reply

GSTX7 Feb. 27 at 8:48 PM

$ATAI Ok. Back in.

0 · Reply

ASTB14 Feb. 27 at 8:39 PM

$ATAI Very great initial data seriously, it proved a lot, and they hit their primary goal (safety), everything else is the cherry on top.

0 · Reply

Bruv99669 Feb. 27 at 7:30 PM

$ATAI

0 · Reply

MexicoCity Feb. 27 at 7:30 PM

$ATAI

0 · Reply

Flarelords Feb. 27 at 7:30 PM

$ATAI Hopefully we can get some more info on investor day next week - looking forward to seeing what comes of it

0 · Reply

Georggggie Feb. 27 at 7:30 PM

$ATAI Really solid tweet by Christian think it was needed.

0 · Reply

Don_Brooks Feb. 27 at 7:29 PM

$ATAI

0 · Reply

TommyDel Feb. 27 at 6:42 PM

$ATAI decided to pull the trigger and get back into the company. Said before I think it’s a great company and happy to be buying into it again Lots to look forward to in the future Welcoming ATAI to my long hold team again

1 · Reply

Abercrombier Feb. 27 at 6:20 PM

$ATAI

0 · Reply

LondonLeaves9845 Feb. 27 at 6:20 PM

$ATAI Market focused on effect size, but Christian’s point was this was a short monitoring window and behavioral change in SAD takes longer to show... def worth a read if you have a couple mins https://x.com/c_angermayer/status/2027419503995342934?s=46

0 · Reply

IndecisiveTrader Feb. 27 at 6:19 PM

$ATAI Good to see Christian address shareholders directly. Main takeaway from his post was safety came through clean and this study did what it was designed to do.

0 · Reply

MonsterSuccess Feb. 27 at 6:19 PM

Market reaction felt like expectations were set for a knockout. Instead this looks more like a de-risking step. $ATAI

0 · Reply

CoopersCup Feb. 27 at 6:18 PM

Christian calling EMP-01 a potential third lead program tells you how management is thinking about this internally. $ATAI

0 · Reply

Cultler Feb. 27 at 6:15 PM

Market sold the news but the key takeaway for me on $ATAI is safety. Primary endpoint met with no serious adverse events. That matters more long term than short-term price action.

0 · Reply

KG_Macro Feb. 27 at 5:59 PM

$ATAI Benzo's work, that's not the problem, the problem is massive addiction/liability issues with them so Dr.'s/insurances won't provide them any longer. If EMP works even close to good as a Benzo, that's awesome news!! (SSRI generally pretty much such, though)

0 · Reply

Sailingsoon Feb. 27 at 5:58 PM

$ATAI https://x.com/c_angermayer/status/2027419503995342934?s=46&ct=rw-null Reshared 👍👍👍👍👍

0 · Reply

WeTheNorth1234 Feb. 27 at 5:58 PM

$ATAI market sold the news but the fundamentals didn’t change

0 · Reply

Tunes444 Feb. 27 at 5:45 PM

$ATAI

0 · Reply

Tunes444 Feb. 27 at 5:40 PM

$ATAI from the man Christian himself https://x.com/c_angermayer/status/2027419503995342934?s=46

3 · Reply

Market Cap	1.25B
Revenue (ttm)	310,000.00
Net Income (ttm)	-149.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,151.61%
Debt to Equity Ratio	0.00

Volume	10,284,041
Avg Vol	5,985,524
Day's Range	N/A - N/A
Shares Out	233.78M
Stochastic %K	10%
Beta	1.59
Analysts	Strong Sell
Price Target	$12.12